KROS - Keros Therapeutics, Inc.

Keros Therapeutics Appoints Anne Prener to its Board of Directors

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.

Jun 25, 2026 12:01 PM • globenewswire.com

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jun 08, 2026 03:18 PM • seekingalpha.com

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.

Jun 01, 2026 12:01 PM • globenewswire.com

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

May 22, 2026 08:11 AM • zacks.com

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

May 22, 2026 08:11 AM • zacks.com

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

May 22, 2026 08:06 AM • zacks.com

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.

May 15, 2026 09:11 AM • zacks.com

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to earnings of $3.62 per share a year ago.

May 14, 2026 06:10 AM • zacks.com

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026.

May 14, 2026 04:00 AM • globenewswire.com

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

Apr 20, 2026 08:46 AM • zacks.com

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

Keros Therapeutics  KROS reshaped its financial profile in 2025 by pairing a major licensing transaction with a shift in development responsibilities. The result was a step-change in reported revenue and a meaningful reduction in internal research and development burden.

Apr 20, 2026 08:41 AM • zacks.com

KROS Rinvatercept: What to Know Before DMD Phase II Starts

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.

Apr 20, 2026 08:30 AM • zacks.com

JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS

JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,941 shares of the company's stock after buying an additional 124,287 shares during the

Apr 06, 2026 12:45 AM • defenseworld.net

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

Apr 03, 2026 08:31 AM • zacks.com

KROS Stock: What to Know About Rinvatercept in DMD

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.

Mar 17, 2026 10:20 AM • zacks.com

KROS: Is the Discount Book Value a Value Trap?

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.

Mar 17, 2026 10:20 AM • zacks.com

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

Mar 17, 2026 10:20 AM • zacks.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts

Keros Therapeutics, Inc. (NASDAQ: KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company.

Mar 12, 2026 10:50 PM • defenseworld.net

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.

Mar 09, 2026 04:00 AM • globenewswire.com

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital (“MGH”) for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis (“ALS”) within the Healey ALS MyMatch program (“ALS MyMatch”), led by the Sean M.

Mar 09, 2026 04:00 AM • globenewswire.com

Jefferies Starts Keros Therapeutics (KROS) at Buy

$107.00 (was $62.02)

Kelly Shi · Jefferies

Nov 05, 2024 01:47 PM • StreetInsider

Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS)

$100.00 (was $62.02)

Srikripa Devarakonda · Truist Financial

Nov 05, 2024 06:06 AM • StreetInsider

Guggenheim Starts Keros Therapeutics (KROS) at Buy

$96.00 (was $55.80)

Vamil Divan · Guggenheim

Sep 22, 2024 10:57 PM • StreetInsider

Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS)

$105.00 (was $44.65)

Joseph Catanzaro · Piper Sandler

Jun 18, 2024 03:57 AM • StreetInsider

BTIG Maintains Buy on Keros Therapeutics, Raises Price Target to $105

$105.00 (was $49.98)

BTIG

Dec 13, 2022 03:49 AM • Benzinga

Keros Therapeutics (KROS) Stock: Why It Surged 11.43% Today

$80.00 (was $31.79)

Julian Harrison · BTIG

Jul 27, 2022 03:59 PM • Pulse 2.0

Keros Therapeutics price target raised to $120 from $90 at Piper Sandler

$120.00 (was $39.92)

Joseph Catanzaro · Piper Sandler

May 18, 2022 06:06 AM • TheFly